Check 35,000+ stocks against 26 valuation models and 37 quality factors

Deltex Medical Group plc (DTXMF) fair value: what the stock is really worth

As of Aug 4, 2026: fair value of Deltex Medical Group plc $0.01, price $0.10, upside -89.5%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US

Thin data Jun 23, 2026

Deltex Medical Group plc

DTXMF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0100 · Strongly overvalued (−89.5%)

!Quality 35/100

!Weak Growth (revenue 5y −13.5 %/yr)

!Loss-making · -87.4% net margin (TTM)

!Moderate debt · negative free cash flow

!Trails peers (1/9)

!Narrow moat 6/100

!Evidence only low, so the estimate is less certain

26 models, one by onewith weight and evidence Growth analysisrevenue history, year by year Quality 35/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Deltex Medical Group plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $0.0013 – $0.4917 · the $0.0952 price screens above the $0.0100 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Deltex Medical Group in your weekly email

Every Wednesday you see whether Deltex Medical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler and pulse contour analysis and monitoring platform. It offers dopplink, a patient interface cable; and pressurewave, an arterial blood pressure signal under the TrueVue brand. The company also provides oesophageal doppler monitoring systems.

Stock analysis

Deltex Medical Group plc (DTXMF) currently trades at $0.0952, while our model-based Fair Value estimate is $0.0100, 89.5% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 86/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Deltex Medical Group plc reported revenue of £2.1M in FY2024 versus £2.4M in FY2020, a compound −3.8%/yr. Reported net income was −£1.8M in FY2024.

Key figures

Market cap $180M · P/S ratio 87.8 · Net margin −87.4% · Return on equity −78.2% · Return on assets (EBIT) −19.1% · Operating margin −39.1% · Revenue (TTM) £2.1M · Revenue growth (YoY) +38.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −90%, DTXMF screens richer than that median.

Notify me when DTXMF reaches fair value

Put DTXMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 35/100

Of which business quality 35 · Market factors (momentum, volatility) 56

Profitability 17

Margins and returns on capital today

Quality Growth 73

Are margins and returns improving?

Cashflow 0

Earnings quality: real cash, not paper profit

Fin. Strength 53

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 100

Calm price path (market factor)

Momentum 40

Price trend over the last 3–12 months (market factor)

52W Momentum 33

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+15.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−3.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−13.5%

Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.7%

’13

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−0.8% (2019) → −77.1% (2024)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss

not computed

DTXMF screens overvalued: fair value 90% below the price. Compare with Abbott Laboratories, →

Compare Deltex Medical Group plc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 1/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 35 · Bottom 25%

Fair Value upside −89.5% · Bottom 25%

Profitability

Return on assets −10.1% · Bottom 25%

Net margin (TTM) −87.4% · Bottom 25%

Operating margin (TTM) −39.1% · Bottom 25%

Growth and dividend

Revenue growth 38.4% · Top 25%

Balance sheet

Debt / equity 1.04× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (TTM) 87.69× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 9

FUTURE (revenue growth)100 · sector 31

PAST (return on equity)0 · sector 11

HEALTH (low debt)48 · sector 97

DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$98.83	$74.79	−24%
Medtronic plc MDT	$87.09	$65.61	−25%
Stryker Corporation SYK	$278.77	$306.65	+10%
Boston Scientific Corporation BSX	$43.65	$48.02	+10%
Edwards Lifesciences Corporation EW	$85.19	$81.94	−4%
Siemens Healthineers AG SHL	€37.86	€35.19	−7%
DexCom, Inc DXCM	$86.68	$95.35	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Deltex Medical Group plc · Fair Value
$0.0100 −90%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/DTXMF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Deltex Medical Group plc · Fair Value</span><br><b style="font-size:20px">$0.0100</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−90%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Deltex Medical Group plc Fair Value". https://www.fairvalue-calculator.com/stock/DTXMF

Frequently asked questions

Is Deltex Medical Group plc (DTXMF) overvalued or undervalued?

As of Jun 23, 2026, our model estimates a fair value of $0.0100 versus the last price from Aug 4, 2026 of $0.0952, about −90% upside (overvalued).

What is the fair value of DTXMF?

Our model-based fair value for Deltex Medical Group plc is $0.0100 (as of Jun 23, 2026), built from audited fundamentals. Last price (from Aug 4, 2026): $0.0952.

What is the quality score of DTXMF?

Deltex Medical Group plc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Deltex Medical Group plc (DTXMF)?

Our model-based price target is the fair value of $0.0100 (as of Jun 23, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.

What is the Deltex Medical Group plc stock forecast for 2026?

Our models put fair value at $0.0100, about −90% upside versus the last price from Aug 4, 2026 of $0.0952 (overvalued). The calculation is refreshed regularly with new filings.

What is the revenue of Deltex Medical Group plc (DTXMF)?

Deltex Medical Group plc reported trailing-twelve-month revenue of about £2.1M (latest available figure, as of Jun 23, 2026).

What is the intrinsic value of Deltex Medical Group plc (DTXMF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Deltex Medical Group plc it is $0.0100 per share (as of Jun 23, 2026), against a price of $0.0952. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).

Is Deltex Medical Group plc stock overvalued or undervalued in 2026?

As of Jun 23, 2026, DTXMF trades above its calculated fair value: price $0.0952, fair value $0.0100, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of DTXMF?

No. The price is what the market pays today ($0.0952); the fair value is what the company's own numbers justify ($0.0100). For Deltex Medical Group plc the two are $0.0852 per share apart. That gap is exactly why we show both numbers side by side.

How much is Deltex Medical Group plc worth?

The market values Deltex Medical Group plc at about $180M (market capitalisation, as of Jun 23, 2026). Per share that is $0.0952; our models calculate a fair value of $0.0100 per share.

How solid is the balance sheet of Deltex Medical Group plc (DTXMF)?

Balance-sheet figures for Deltex Medical Group plc (as of Jun 23, 2026): return on equity −78.2%, debt of 1.04 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.

How far is DTXMF from its 52-week high?

Deltex Medical Group plc trades at $0.0952, at its 52-week high of $0.0952 and at the low of $0.0952 (as of Aug 4, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0100 is for.

Which stocks are comparable to Deltex Medical Group plc?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Deltex Medical Group plc stock attractive at the current price?

The data as of Jun 23, 2026: price $0.0952, calculated fair value $0.0100 (−90%), Quality Score 35/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of DTXMF calculated?

We run Deltex Medical Group plc through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0100, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Deltex Medical Group plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Deltex Medical Group plc (DTXMF)?

The latest price we hold is from Aug 4, 2026 and stands at $0.0952. Our model-based fair value is $0.0100, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Deltex Medical Group plc right now?

Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Deltex Medical Group plc

How large is the market capitalisation of Deltex Medical Group plc (DTXMF)?

The market capitalisation of Deltex Medical Group plc is $180M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Deltex Medical Group plc (DTXMF)?

The price-to-sales ratio of Deltex Medical Group plc is 87.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the net margin of Deltex Medical Group plc (DTXMF)?

The net margin of Deltex Medical Group plc is −87.4% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Deltex Medical Group plc (DTXMF)?

The return on equity (ROE) of Deltex Medical Group plc is −78.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Deltex Medical Group plc (DTXMF)?

On an EBIT basis the return on assets of Deltex Medical Group plc is −19.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Deltex Medical Group plc (DTXMF)?

The operating margin of Deltex Medical Group plc is −39.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Deltex Medical Group plc (DTXMF)?

Revenue at Deltex Medical Group plc is growing +38.4% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Deltex Medical Group plc (DTXMF) generate?

The free cash flow of Deltex Medical Group plc is −£490K (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Deltex Medical Group plc (DTXMF) carry?

The net debt of Deltex Medical Group plc is £1.8M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Deltex Medical Group plc in the live analysis

One click puts Deltex Medical Group plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.